CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
7th European Post-Chicago Melanoma / Skin Cancer Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Schilling on the Importance of Distinguishing Ocular Melanoma
Dr. Daud on the Combinations of Immunotherapy for Melanoma
Dr. Andtbacka on the OPTiM Results of T-VEC for Melanoma
Oncology Conference Articles
Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced Melanoma
The addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate in patients with unresected stage IIIb to IV melanoma.
Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma
Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.
PD-1/PD-L1 Inhibitors Arrive in Merkel Cell Carcinoma
Immune checkpoint inhibitors against PD-1 and PD-L1 are showing promise across clinical trials for patients with Merkel cell carcinoma.
Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma
Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.
Dabrafenib Shows Remarkable Intracranial Activity in Patients With BRAF-Mutant Melanoma and Brain Metastases
Monotherapy with potent BRAF inhibitor dabrafenib (Tafinlar) resulted in a disease control rate of 83% in patients with
-mutant melanoma and brain metastases.
Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma
Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.
Adjuvant PD-1 Inhibition on Horizon in Melanoma
Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.
Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma
Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Harvard Expert Sees Potential in BCL-2 Combos
Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy
Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.